Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...